Roxanne Achong-Coan, OD
Corneal and Contact Management · Ocoee, FLNPI 1366463275
Payments from drug & device makers
Across 529 payments — averaging $577.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$292K
- Topcon Healthcare, Inc.$4K
- Bausch & Lomb Americas Inc.$1K
- Alcon$1K
- Notal Vision, Inc.$960
- Johnson & Johnson Vision Care, Inc.$884
- plus $5K from 21 others
Across 3 payments — averaging $25,724 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coopervision Inc.$77K
What the payments were for
- Consulting fees$20,04812%
- Speaking & faculty fees$95,81856%
- Travel & lodging$40,06923%
- Food & beverage$15,0399%
- Entertainment$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 288 | $292,311 |
| Topcon Healthcare, Inc. | 6 | $4,332 |
| Bausch & Lomb Americas Inc. | 25 | $1,239 |
| Alcon | 34 | $1,203 |
| Notal Vision, Inc. | 32 | $960 |
| Johnson & Johnson Vision Care, Inc. | 17 | $884 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $680 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $547 |
| Oyster Point Pharma, Inc. | 20 | $528 |
| Harrow Eye, LLC | 18 | $512 |
| Kala Pharmaceuticals, Inc. | 17 | $349 |
| Sun Pharmaceutical Industries Inc. | 15 | $340 |
| Tarsus Pharmaceuticals, Inc. | 10 | $262 |
| Glaukos Corporation | 3 | $255 |
| Dompe US, Inc. | 7 | $253 |
| Thea Pharma Inc. | 1 | $186 |
| AbbVie(2 entities) | 4 | $158 |
| Optovue, Inc. | 2 | $144 |
| Novartis | 5 | $87 |
| ABB Con-cise Optical Group LLC | 2 | $80 |
| Optos, Inc. | 2 | $66 |
| Rxsight Inc | 1 | $64 |
| Visionix USA, Inc | 1 | $40 |
| Eyevance Pharmaceuticals LLC | 2 | $32 |
| Biotissue Holdings Inc. | 1 | $23 |
| Carl Zeiss Meditec USA, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MyDay Contact Lens$55,774
- MiSight Contact Lens$33,740
- Multiple Brands Contact Lens$28,348
- Clariti Contact Lens$13,625
- Non-Product Brand Specific$5,330
- CVI Contact Lens$3,459
- Biofinity Contact Lens$2,000
- INFUSE$537
- One Series Ultra IOL Delivery System$535
- Acuvue$501
- MIEBO$237
- AIR OPTIX$166
- Paragon CRT$162
- Photrexa Viscous and Photrexa$142
- Ortho-K Contact Lens$137
- Oxervate$125
- CEQUA$125
- EYSUVIS$123
- VEVYE$122
- VYZULTA$122
How this compares
$305,573 in reported general payments places this provider in the 95th percentile of 67 corneal and contact management providers in Florida.
See all corneal and contact management providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 11 | $7,646 |
| ValacyclovirValacyclovir Hcl | 12 | $426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $1,239 | $7,64611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 corneal and contact management providers in Florida.
Other corneal and contact management in Ocoee
- Flana LevandoOcoee$3K
- Cory CollierBradenton$35K
- Justine SiergeyOrlando$21K
- Tamara MauleBoca Raton$12K
- Kenneth MallerOakland Park$12K
- Terry van der HeydenNaples$8K
- Brian ArmitageJacksonville$8K
- Gordon PennViera$7K
- Denise Burns LegrosMelbourne$6K
- Jose ArnaoGainesville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.